scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 54.17 percent decrease over losses of $(0.24) per share from the same period last year.
Nvidia Positioned for Massive Growth as Core Holding in Generative AI, Analyst Says
Tigress Financial Partners analyst Ivan Feinseth reiterated a Buy rating on Nvidia Corp (NASDAQ: NVDA) and raised the
